Safety and Efficacy of TRx0237 in Subjects With Alzheimer's Disease Followed by Open-Label Treatment

NCT03446001 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

598

Enrollment

INDUSTRY

Sponsor class

Conditions

Alzheimer Disease

Interventions

DRUG: TRx0237 16 mg/day
DRUG: Control
DRUG: TRx0237 8 mg/day

Sponsor

TauRx Therapeutics Ltd